Stay updated with breaking news from Abbott Pathology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Australian Clinical Labs, the No.3 player in the pathology market, has not given up in its chase for ailing No.2 player Healius.
Healius Limited (ASX:HLS – Get Free Report) insider Kathryn (Kate) McKenzie bought 53,000 shares of Healius stock in a transaction on Monday, December 4th. The stock was acquired at an average cost of A$1.52 ($1.01) per share, with a total value of A$80,560.00 ($53,350.99). Healius Stock Performance The company has a current ratio of 0.55, […]
There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.
Healius Limited (ASX:HLS – Get Free Report) insider Jennifer (Jenny) Macdonald acquired 8,000 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were purchased at an average price of A$2.53 ($1.63) per share, with a total value of A$20,232.00 ($13,052.90). Healius Stock Performance The company has a quick ratio of […]
Increasing Healthcare Expenditure and Technological Advancement Along With the New Innovations Are Likely to Aid the Market Growth of the Pathological Examination Market Report.